Canaccord Genuity reaffirmed their buy rating on shares of CryoLife, Inc. (NYSE:CRY) in a report released on Monday. Canaccord Genuity currently has a $25.00 target price on the medical equipment provider’s stock.
Several other research analysts have also weighed in on CRY. BidaskClub lowered CryoLife from a hold rating to a sell rating in a research report on Tuesday, August 1st. Zacks Investment Research raised CryoLife from a sell rating to a hold rating in a research report on Monday, August 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. CryoLife presently has a consensus rating of Buy and an average price target of $23.63.
CryoLife (NYSE CRY) opened at 21.30 on Monday. CryoLife has a 12 month low of $14.03 and a 12 month high of $24.00. The stock has a market cap of $712.40 million, a P/E ratio of 64.55 and a beta of 0.92. The company’s 50-day moving average price is $21.91 and its 200-day moving average price is $19.19.
CryoLife (NYSE:CRY) last posted its quarterly earnings data on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.02. CryoLife had a return on equity of 7.41% and a net margin of 6.16%. The business had revenue of $47.80 million for the quarter, compared to analysts’ expectations of $47.02 million. During the same quarter last year, the firm earned $0.13 earnings per share. The business’s revenue was up 1.5% on a year-over-year basis. Equities analysts forecast that CryoLife will post $0.43 earnings per share for the current year.
WARNING: This piece of content was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/2956330/cryolife-inc-cry-earns-buy-rating-from-canaccord-genuity.html.
In other CryoLife news, Director James Benson sold 2,000 shares of CryoLife stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $22.80, for a total value of $45,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO James P. Mackin sold 125,000 shares of CryoLife stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $22.01, for a total value of $2,751,250.00. Following the completion of the transaction, the chief executive officer now owns 398,399 shares of the company’s stock, valued at $8,768,761.99. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 171,050 shares of company stock valued at $3,769,825. 6.00% of the stock is currently owned by insiders.
A number of hedge funds have recently modified their holdings of CRY. Municipal Employees Retirement System of Michigan boosted its stake in CryoLife by 3.2% in the first quarter. Municipal Employees Retirement System of Michigan now owns 6,150 shares of the medical equipment provider’s stock valued at $102,000 after acquiring an additional 190 shares during the period. Mason Street Advisors LLC raised its holdings in shares of CryoLife by 7.4% during the first quarter. Mason Street Advisors LLC now owns 6,324 shares of the medical equipment provider’s stock valued at $105,000 after buying an additional 438 shares during the last quarter. State of Alaska Department of Revenue raised its holdings in shares of CryoLife by 80.8% during the second quarter. State of Alaska Department of Revenue now owns 5,387 shares of the medical equipment provider’s stock valued at $107,000 after buying an additional 2,407 shares during the last quarter. First Mercantile Trust Co. raised its holdings in shares of CryoLife by 5.6% during the second quarter. First Mercantile Trust Co. now owns 5,448 shares of the medical equipment provider’s stock valued at $109,000 after buying an additional 291 shares during the last quarter. Finally, Creative Planning raised its holdings in shares of CryoLife by 3.0% during the second quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock valued at $136,000 after buying an additional 200 shares during the last quarter. Institutional investors own 68.44% of the company’s stock.
CryoLife Company Profile
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.